Muscle cells and motoneurons differentially remove mutant SOD1 causing familial amyotrophic lateral sclerosis by Onesto, Elisa et al.
Amyotrophic lateral sclerosis (ALS) is a fatal adult onset
neurodegenerative disease. ALS is characterized by the
progressive loss of motoneurons in the cerebral cortex, in the
brain stem and in the anterior horns of the spinal cord
(Pasinelli and Brown 2006). ALS has been reported to occur
in sporadic and familial (fALS) forms, which are clinically
indistinguishable. Up to now, several genes have been linked
to fALSs. One of these is the gene coding for the superoxide
dismutase 1 (SOD1), which accounts for approximately 15%
of fALS cases. Most SOD1 alterations are point mutations,
which are thought to destabilize protein conformation lead-
ing to misfolding (Seetharaman et al. 2009). The misfolded
SOD1 may then perturb several motoneuronal functions. It
has been proposed that misfolded proteins may either acquire
aberrant enzymatic activities, impair axonal transport, form
intracellular aggregates, saturate the proteasome, induce
mitochondrial dysfunctions, etc. (Pasinelli and Brown
2006; Cozzolino et al. 2008; Seetharaman et al. 2009).
Several studies, with conﬂicting results, have been performed
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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal motoneuronal
disease which occurs in sporadic or familial forms, clinically
indistinguishable. About 15% of familial ALS cases are linked
to mutations of the superoxide dismutase 1 (SOD1) gene that
may induce misfolding in the coded protein, exerting neuro-
toxicity to motoneurons. However, other cell types might be
target of SOD1 toxicity, because muscle-restricted expression
of mutant SOD1 correlates with muscle atrophy and moto-
neurons death. We analysed the molecular behaviour of mu-
tant SOD1 in motoneuronal NSC34 and muscle C2C12 cells.
We found that misfolded mutant SOD1 clearance is much
more efﬁcient in muscle C2C12 than in motoneuronal NSC34
cells. Mutant SOD1 forms aggregates and impairs the pro-
teasome only in motoneuronal NSC34 cells. Interestingly,
NSC34 cells expressing mutant SOD1 are more sensitive to a
superoxide-induced oxidative stress. Moreover, in muscle
C2C12 cells mutant SOD1 remains soluble even when pro-
teasome is inhibited with MG132. The higher mutant SOD1
clearance in muscle cells correlates with a more efﬁcient
proteasome activity, combined with a robust autophagy acti-
vation. Therefore, muscle cells seem to better manage mis-
folded SOD1 species, not because of an intrinsic property of
the mutant protein, but in function of the cell environment,
indicating also that the SOD1 toxicity at muscle level may not
directly depend on its aggregation rate.
Keywords: amyotrophic lateral sclerosis, autophagy, moto-
neuron diseases, muscle cells, proteasome, SOD1.
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rons, or other cell types (such as glial cells, microglia,
Schwann cells, and/or muscle cells) may be affected, thus
playing a role in the disease. With regard to the muscle cells,
skeletal muscle dysfunctions and neuromuscular junction
degeneration occur long before disease onset and motoneu-
ron death (Frey et al. 2000; Fischer et al. 2004). Moreover,
the expression of mutant SOD1 in skeletal muscle induces
progressive muscle atrophy (Dobrowolny et al. 2008b), and
the damaged muscle cells also have impact on the survival of
motoneurons located in the anterior horns of the spinal cord
(Wong and Martin 2010). This suggests that motoneuronal
degeneration might occur as a consequence of the loss of
the target muscle cells, and the consequent degeneration of
the neuromuscular junction and of the axonal processes. A
contribution of the lack of muscle-derived growth factors,
which normally preserve motoneurons from death, cannot
also be excluded (Musaro et al. 2001; Kaspar et al. 2003;
Dobrowolny et al. 2005, 2008a; Palazzolo et al. 2009).
However, motoneuronal restricted expression of mutant
SOD1 is also sufﬁcient to cause ALS (Wang et al. 2008).
Therefore, both motoneurons and muscle may be target of
mutant SOD1 toxicity and possibly both may synergistically
contribute to accelerate the onset and the progression of ALS.
We already characterized the molecular behaviour of
mutant SOD1 in immortalized motoneurons and described
potential mechanisms by which this misfolded protein may
become neurotoxic (Sau et al. 2007; Crippa et al. 2010b).
We found that the formation of high molecular weight
species of mutant SOD1 generates intracellular aggregates,
which correlates with a marked proteasome impairment and
alters SOD1 intracellular distribution (Sau et al. 2007). This
also decreases SOD1 bioavailability resulting in a deprotec-
tion from free radical species and the consequent damage to
genomic DNA (Sau et al. 2007). It is unknown whether the
toxicity of mutant SOD1 in muscle cells is caused by the
same molecular toxic mechanisms active in motoneurons.
Moreover, it is unclear whether muscle cells may be able to
better manage the misfolded SOD1 species, thought to be
formed as an intrinsic property of the mutant protein, and
occurring independently from the cell environment (Dobson
2003).
To this purpose, we compared the biochemical behaviour
and degradative processes of wt and mutant SOD1 protein in
two different cell models: an immortalized motoneuronal cell
line (NSC34) and a muscle cell line (C2C12) maintained
either in proliferating or differentiating conditions. The
results have shown that misfolded mutant SOD1 is cleared
at much faster rate in muscle cells than in motoneuronal cells,
preventing the intracellular accumulation of insoluble SOD1
species in muscle cells. The increased clearance of mutant
SOD1 in muscle cells is apparently caused by a more
efﬁcient proteasome activity, combined with a robust
activation of the autophagic system.
Material and methods
Materials
All chemicals have been obtained from Sigma (Sigma Aldrich,
Milano, Italy). Restriction enzymes and ligase have been obtained
from GE Healthcare (Little Chalfont, Buckinghamshire, UK).
Plasmids
pEGFP-N1 encodes the GFPmut1 variant, a red-shifted variant, of
soluble wild-type green ﬂuorescent protein (GFP) (Clontech Labo-
ratories Inc., Mountain View, CA, USA). pDsRed-Monomer-C1
(Clontech Laboratories Inc.) encodes DsRed-Monomer, a mono-
meric mutant derived from the tetrameric Discosoma sp. red
ﬂuorescent protein DsRed (kex = 557 nm, kem = 592 nm).
pCDNA3-wtSOD1 and pCDNA3-G93A-SOD1 express wtSOD1
and mutant G93A-SOD1 (Tortarolo et al. 2004). pECFP-wtSOD1
and pECFP-G93A-SOD1 express wt and mutant human SOD1
tagged with cyan ﬂuorescent protein (CFP) (Sau et al. 2007). GFPu
(from R. Kopito, USA) and YFPu express a CL1 tagged-GFP or
tagged-YFP respectively, two proteasome activity reporter proteins
(Rusmini et al. 2007; Sau et al. 2007). The plasmids pEGFP-
wtSOD1 and pEGFP-G93A-SOD1 express GFP-tagged human
SOD1 (Crippa et al. 2010b). pRFP-LC3 expresses a RFP-tagged
rat LC3 (from A. Tolkovsky, Great Britain) (Bampton et al. 2005).
pDest-mCherry-p62 expresses a Cherry-tagged p62 (from Terje
Johansen, University of TromsØ, Norway).
Cell cultures and transfection
The immortalized motoneuronal NSC34 cell line (Cashman et al.
1992) has been routinely maintained and transfected with Lipo-
fectamine (Invitrogen, San Giuliano Milanese, Italy)/transferrin
(Sigma Aldrich; 2 : 1) as previously described (Simeoni et al.
2000).
The myoblast C2C12 cell line was originally obtained from
American Type Culture Collection (Rockville, MD, USA). The
cell line was routinely maintained in Dulbecco’s modiﬁed Eagle’s
medium (Biochrom KG, Berlin, Germany) supplemented with
1 mM glutamine, 1 mM sodium pyruvate, 100 U/mL penicillin,
100 lg/mL streptomycin, and 10% fetal bovine serum (Invitro-
gen) at 37 C with 5% CO2. Differentiation in muscle C2C12
(C2C12-D) cultures was induced by replacing the growth medium
with differentiation medium (2% horse serum, Invitrogen, in
Dulbecco’s modiﬁed Eagle’s medium) after the cells reached 70%
conﬂuence. Muscle C2C12 cells have been routinely transfected
with Lipofectamine 2000 (Invitrogen) following Manufacturers’
instructions.
Fluorescence and microscopy
Motoneuronal NSC34 cells was plated at 70 000 cells/mL, muscle
C2C12 cells at 60 000 cells/mL, in 12-well multiwell plates
containing 18-mm glass coverslips; after 24 h the cells have been
transfected with 1 lg of plasmids coding for GFP-wtSOD1, GFP-
G93A-SOD1, CFP-wtSOD1 or CFP-G93A-SOD1. Co-transfections
were performed adding 0.05 lg of plasmid coding for YFPu or
0.3 lg of plasmid coding for mRFP-LC3 or mCherry-p62. For
motoneuronal NSC34 cells were added 3 lL of transferrin solution
and 2 lL of Lipofectamine; for muscle C2C12 cells 4 lLo f
Lipofectamine 2000 were added. Cells were allowed to grow for
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dehyde and 4% sucrose, and then in cold methanol. Nuclear staining
was achieved by incubation with 4¢,6-diamino-2-phenylindole
(DAPI) [0.25 lg/mL in phosphate-buffered saline (PBS)] for
1 min at 20 C. The coverslips were mounted in Mowiol 
(Calbiochem, San Diego, CA, USA) and examined with an Axiovert
200 microscope (Zeiss Instr., Oberkochen, Germany) equipped with
ﬂuorescein isothiocyanate (FITC)/tetramethylrhodamine isothiocya-
nate (TRITC)/DAPI or with CFP/YFP sets of ﬁlters. Fluorescence
images were captured with a Photometric CoolSnap CCD camera
(Ropper Scientiﬁc, Trenton, NJ, USA). Images were processed using
Metamorph software (Universal Imaging, Downingtown, PA, USA).
To evaluate the presence of SOD1 aggregates, GFP-SOD1 (wt or
G93A) expressing cells were analysed by ﬂuorescence microscopy
48 h after transfection. GFP-SOD1 aggregates were estimated using
aP L1 0 ·/20 eyepiece with graticules (100 mm · 100 mm in a 100
grid divisions). Transfected cells were evaluated by their staining
pattern as diffusely labelled, or as containing aggregates. The
percentage of GFP-SOD1 cells with aggregates was obtained
dividing the number of cells bearing GFP-SOD1 aggregates by
the total number of transfected cells. At least 60 cells/ ﬁeld were
counted, and three ﬁeld for each coverslips were analysed. The
experiments were performed in triplicate.
Western blot analysis and ﬁlter retardation assay
For western blot and ﬁlter retardation assays, cells were plated in
12-well multiwells at 80 000 cells/mL density for motoneuronal
NSC34 cells, and at 65 000 cells/mL density for muscle C2C12
cells. Transient transfections were performed co-transfecting 1 lg
of pCDNA3, wt or G93A-SOD1 plasmids with 0.05 lg of YFPu
plasmids for each sample. Motoneuronal NSC34 cells were
transfected with 3 lL of transferrin solution and 2 lL of Lipofec-
tamine for each sample, whereas for muscle C2C12 cells were
added 4 lL of Lipofectamine 2000. To inhibit proteasome activity,
MG132 (Sigma Aldrich) was used at doses of 10 lM for 15 h.
After 48 h from transfection, cells were harvested and centrifuged
5 min at 100 g at 4 C; the pellets of cells were resuspended in PBS
(added of a protease inhibitors cocktail, Sigma Aldrich) and
homogenized using slight sonication. Total proteins were deter-
mined with the bicinchoninic acid method (BCA assay, Pierce,
Rockford, IL, USA). Western immunoblot analysis was performed
on 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis
loading 30 lg of total proteins. Samples were then electro-
transferred to nitrocellulose membranes (Trans-blot, Bio-Rad
Laboratories, Hercules, CA, USA) using a liquid transfer apparatus
(Bio-Rad Laboratories). Nitrocellulose membranes were treated
with a blocking solution containing 5% non-fat dry milk in Tween-
TBS (TBS-T, 20 mM TrisHCl, pH 7.5, 0.5 M NaCl, 0.05% Tween-
20) for 1 h and then incubated with the primary antibodies: (a)
peroxidase labelled goat anti-GFP (Vector Laboratories, Burlin-
game, CA, USA; dilution 1 : 5000 in TBS-T) to detect YFPu; (b)
rabbit polyclonal anti-LC3 (Sigma Aldrich; dilution 1 : 1000 in
milk); (c) rabbit polyclonal anti-Cu/Zn superoxide dismutase SOD1
(SOD-100; Assay Designs; dilution 1 : 1000 in milk) to detect the
wt and G93A-SOD1 proteins; (d) goat polyclonal anti-Actin (Actin
I-19; Santa Cruz Biotechnology, Santa Cruz CA, USA, dilution
1 : 1000 in milk) to detect total actin. Immunoreactivity was
detected using the following secondary peroxidase-conjugated
antibodies: goat anti-rabbit (sc-2004; Santa Cruz Biotechnology)
was used to identify the anti-SOD1 and the anti-LC3; donkey anti-
goat (sc-2020; Santa Cruz Biotechnology) was used to identify the
anti-Actin antibody. The immunoreactive regions were then
visualized using the enhanced chemiluminescence detection kit
reagents (ECL; GE Healthcare). The same membranes were
subsequently processed with different antibodies to detect the
levels of proteins in the same samples loaded on the gel, after
stripping for 30 min at 37 C in restore western blotting stripping
buffer (Pierce).
Filter retardation assay was performed by sample ﬁltration
through a 0.2 lm cellulose acetate membrane (Whatman, Dassel,
Germany) using a slot-blot apparatus (Bio-Rad Laboratories) and
loading 0.75 lg of total proteins. Slot-blots were probed as
described for western blots. Optical intensity of samples assayed
with ﬁlter retardation assay was detected and analysed using NIH
ImageJ software.
Cytoﬂuorimetric analysis
Samples for cytoﬂuorimetric analysis were obtained from NSC34,
C2C12 and C2C12-D cells, plated in 12-well multiwell plates at
90 000 cells/mL density (NSC34 cells) or 60 000 cells/mL density
(C2C12 and C2C12-D cells), transfected with (a) 1 lg of pEGFP-
N1 plasmid; (b) 1 lg of GFP-SOD1, wt or G93A, plasmid; (c) or
co-transfected with 0.1 lg of GFPu and 0.2 lg of DsRed-Monomer
and 1 lg of pcDNA3. The transfected cells were harvested and
centrifuged 5 min at 100 g at 4 C; the cell pellets were resuspended
in 400 lL of 4% paraformaldehyde, incubated at 20 C for 10 min
on a rotator and then centrifuged 5 min at 100 g at 4 C. Once
supernatant was aspirated from cell preparation, the pellets was
resuspended in 300 lL of PBS. Cell ﬂuorescence was detected
using FACS Calibur (BD Pharmingen). Flow cytometry results were
analysed using CellQuest (BD Pharmigen) program analysis
software.
To detect superoxide production, cells were labelled with
MitoSOX  Red mitochondrial superoxide indicator (Molecular
Probes, Eugene, OR, USA). MitoSOX  reagent stock solution
(3 mM) was diluted 1 : 1000 in HBSS/Ca/Mg buffer (10 mM
HEPES pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2 1.8 mM
CaCl2)a t3 7  C. MitoSOX  reagent working solution (3 lM) was
used to replace cell medium, fully covering the cells and incubating
for 1 h at 37 C, keeping the samples protected from light. The
medium was removed and samples washed with HBSS at 37 C and
then collected in 300 lL of PBS. Cells were analysed in cyto-
ﬂuorimeter analysis without ﬁxing in paraformaldehyde (kex =
510 nm, kem = 580 nm; FL2 channel) (Batandier et al. 2002).
Proteasome activity
Proteasome assays were performed as described by Allen et al.
(2003). Cells were plated in 6-well multiwells at 80 000 cells/mL
density for motoneuronal NSC34 cells, and at 70 000 cells/mL
density for muscle C2C12 cells; C2C12-D cells were allowed to
differentiate for 48 h. Cells were washed with ice-cold PBS and then
harvested and centrifuged at 100 g for 5 min, at 4 C. Pellets
resuspended in 0.3 mL of proteasome extract buffer (20 mM Tris/
HCl, pH 7.4, containing 0.1 mM EDTA, 1 mM 2-mercaptoethanol,
5 mM ATP, 20% v/v glycerol, and 0.04% v/v Nonidet P-40) were
homogenized by several passages through a 21-gauge needle, and
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supernatant. Total proteins were determined with the bicinchoninic
acid method (BCA assay; Pierce). Proteasome assay reaction
mixtures consisted of 50 mM HEPES/KOH, pH 8.0, containing
5 mM EGTA, 100 lg of cells extract protein per mL of assay
reaction. The reactions were initiated by adding the appropriate
proteasome substrates conjugated with aminomethylcoumarin
(AMC) and incubating the reactions at 37 C for 45 min. Proteasome
substrates used are: (i) the peptide Suc-LLVY-AMC at 50 lM, to
detect chimotryptic activity; (ii) the peptide Z-ARR-AMC at
100 lM, to detect tryptic activity and (iii) the peptide Z-LLE-
AMC at 100 lM, to detect post-acidic activity. Hydrolysis of the
peptides induces the release of AMC and the resulting ﬂuorescence
was measured at 340 nm excitation and 460 nm emission using a
spectroﬂuorimeter (Victor, Perkin Elmer, MA, USA).
mRNA expression analysis
For real-time PCR analysis cells were plated in 6-well multiwells
plates at 80 000 cells/mL density for motoneuronal NSC34 cells and
at 65 000 cells/mL density for muscle C2C12 cells. After 24 h, cells
have been transfected with 2 lg of plasmids coding for pCDNA3,
wt or G93A-SOD1. For motoneuronal NSC34 cells were added
6 lL of transferrin solution and 4 lL of Lipofectamine were added
for each sample; for muscle C2C12 cells were added 8 lLo f
Lipofectamine 2000 for each sample. Forty-eight hours from
transfection, cells were harvested in 4 M guanidium isothiocyanate
(containing 25 mM sodium citrate pH 7.5, 0.5% sarcosyl and 0.1%
2-mercaptoethanol) and total RNA was isolated by phenol–chloro-
form extraction, according to Chomczynski and Sacchi (1987).
Quantiﬁcation was carried out by absorption at 260 nm. For reverse
transcription, an aliquot of total RNA (1 lg) was treated for 15 min
at 20 C with 1 U of DNaseI (Sigma). After having heat-inactivated
DNaseI, 1 lg of each sample was reverse-transcribed using the
High-Capacity cDNA Reverse Transcription Kit (PE Applied
Biosystems, Monza, Italy) according to the manufacturer’s instruc-
tions, in a 25 lL volume. Primers for selected genes were designed
via the primer Express software (PE Applied Biosystems) and
purchased from Euroﬁns MWG Operon (Ebersberg, Germany). The
sequences of primers were as follows: mMAP-LC3b: 5¢-CGT CCT
GGA CAA GAC CA-3¢ (forward), 5¢-CCA TTC ACC AGG AGG
AA-3¢ (reverse); mp62: 5¢-AGG GAA CAC AGC AAG CT
(forward), 3¢-GCC AAA GTG TCC ATG TTT CA (reverse);
GAPDH:5 ¢-CCA GAA CAT CAT CCC TGC AT-3¢ (forward), 5¢-
CAG TGA GCT TCC CGT TCA-3¢ (reverse). The evaluated
efﬁciency of each set of primers was close to 100% for both target
and reference gene. Real-time PCR was performed using the ABI
Prism 7000 sequence detection system (PE Applied Biosystems) in
a2 5lL total volume, using the iTaq SYBR Green Supermix (Bio-
Rad Laboratories), using 500 nmol primers. PCR cycling conditions
were as follows: 94 C for 10 min, 35 cycles at 94 C for 15 s, and
60 C for 1 min. Melting curve analysis was always performed at the
end of each PCR assay to control for speciﬁcity. Data were
expressed as Ct values and used for the relative quantiﬁcation of
targets with the DDCt calculation. To exclude potential bias because
of averaging data transformed through the equation 2
)DDCt to give
N-fold changes in gene expression, all statistics were performed
with DCt values. Each experiment was carried out twice, with four
independent samples. Each sample was run in duplicate wells.
Statistical analysis
Statistical analysis has been performed using one-tailed Student’s
t-test for two group comparisons; one-way or two-way ANOVA for
three or more group comparisons using the PRISM software
(GraphPad, San Diego, CA, USA).
Results
As recent data have suggested that the skeletal muscle could
be a primary target of mutant SOD1 toxicity in fALS, in this
study we analysed the biochemical behaviour of mutant
SOD1 and its potential deleterious effects in muscle cells,
compared with immortalized motoneurons.
Biochemical behaviour of mutant SOD1 in motoneuron and
muscle cells
We initially investigated whether mutant SOD1 forms
intracellular aggregates in cultured muscle cells. Figure 1a
shows that wtSOD1 is diffusely distributed both in moto-
neurons and in muscle C2C12 cells (either in undifferenti-
ated/proliferating or differentiating conditions, C2C12 or
C2C12-D respectively). As already reported, mutant G93A-
SOD1 is excluded from the nuclei and accumulated into
aggregates in motoneuronal NSC34 cells (Sau et al. 2007).
On the contrary, in muscle C2C12 and C2C12-D cells the
distribution of the mutant G93A-SOD1 was very similar to
that observed with wtSOD1. Almost no mutant SOD1
aggregates were found in these conditions, indicating that
intracellular processing of misfolded mutant G93A-SOD1
differs between neuronal and muscle cells. As ﬂuorescence
microscopy analysis indicated that the number of mutant
SOD1-positive cells differs between NSC34 and C2C12 cells
(data not shown), we wanted to quantify the transfection
efﬁciency in the three cell types included in the study. This
has been estimated by transfecting the soluble EGFP and
counting ﬂuorescence-positive cells in cytoﬂuorimetric anal-
ysis (Fig. 1b). It clearly appears that proliferating C2C12
cells are transfected with an efﬁciency which is approxi-
mately 25% less that NSC34, whereas differentiating C2C12
cell transfection efﬁciency is about half of that measured
in NSC34 cells. Keeping this in mind, we quantiﬁed the
percentage of cells containing aggregates by a direct
estimation of an identical large number of GFP-SOD1s
transfected cells in ﬂuorescence microscopy analysis. The
data (Fig. 1c) demonstrated that about 30% of total trans-
fected motoneuronal NSC34 cells contained intracellular
mutant SOD1 aggregates, while only a negligible percentage
of muscle C2C12 cells (either prior or during differentiation)
were positive for intracellular mutant G93A-SOD1 aggre-
gates. No aggregates have been observed in wtSOD1
expressing cells. Western blot analysis (Fig. 1d) revealed
that in all cell type tested the levels of the monomeric mutant
SOD1 is lower than that of the wtSOD1. The quantiﬁcation
of the monomeric mutant SOD1 levels in the three cell types
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differences in wt versus mutant SOD1 levels and aggregation
rate found in NSC34 and C2C12 cells, these effects cannot
be simply due to transfection efﬁciency (as previously
estimated with the EGFP cytoﬂuorimetric analysis, see
Fig. 1b). Together these data suggest that the reduced levels
of monomeric mutant SOD1 might be related to either a
partial sequestration into insoluble oligomeric species
(Fig. 1c) or to its increased cellular clearance or to both
phenomena. In the case of motoneuronal NSC34 cells, we
have already demonstrated that, intracellular accumulation of
misfolded proteins may generate different multi-homomeric
or heteromeric species, visible in ﬂuorescence microscopy as
inclusions (Sau et al. 2007; Crippa et al. 2010b).
To better clarify this point, we also performed cytoﬂuori-
metric experiments to measure the total levels (monomeric
plus oligomeric species) of GFP-tagged SOD1s. The analysis
considered only GFP-positive transfected cells in order to
normalize for transfection efﬁciency. The results are reported
in Fig. 1f, and show that, in NSC34 cells, in contrast to the
data obtained for the monomeric SOD1 in western blot, the
total amount of mutant SOD1 remained unchanged when
compared with wtSOD1. On the contrary, the amount of total
mutant SOD1 was dramatically reduced when compared with
wtSOD1 in both C2C12 and C2C12-D cells. These data
strongly support the notion that mutant SOD1 clearance is
higher in C2C12 cells, than in NSC34 cells. To further
support this observation, we quantify the total insoluble
species of mutant SOD1 using the ﬁlter retardation assay. This
experiment excludes that, in muscle C2C12 cells, mutant
SOD1 might generate low-molecular weight insoluble species
which are not in the aggregate form, because these species
might have a limited size that does not allow their identiﬁ-
cationin ﬂuorescence microscopy analysis. The data, reported
in Fig. 1g, demonstrated that large amounts of insoluble
mutant SOD1 accumulated in motoneuronal NSC34 cells
already in basal conditions. Mutant SOD1 insoluble species
massively accumulated when proteasome activity was
blocked with the proteasome inhibitor MG132. This supports
the notion that proteasome is involved in mutant misfolded
SOD1 degradation. However, both in proliferating and
differentiating muscle C2C12 cells, mutant SOD1 accumu-
lation was comparable to the very low levels found for
wtSOD1, in basal conditions. In muscle cells, mutant SOD1
insoluble species were observed only after MG132-mediated
proteasome blockage. Thus, muscle C2C12 cells are able to
correctly handle the fraction of misfolded mutant SOD1 that
usually accumulate in immortalized motoneurons. The deg-
radative system in muscle C2C12 cells not only prevents the
formation of large misfolded protein inclusions, but also
prevents the accumulation of species of smaller size (micro-
aggregates). The reduction of monomeric mutant SOD1
(determined for C2C12 cells in Fig. 1d and e) must be due to
an increased clearance of the misfolded protein that prevents
its aggregation. Moreover, the fact that proteasome inhibition
resulted in insoluble species accumulation proves that, also in
muscle cells, the proteasomal degradative system is involved
in the clearance of misfolded SOD1.
As NSC34 and C2C12 cells differ in their capacity to
remove mutant SOD1, we wanted to determine whether this
Fig. 1 Biochemical behaviour of wt and mutant SOD1 in motoneu-
ronal NSC34 cells and in muscle C2C12 cells. (a) High resolution
ﬂuorescent microscopy analysis on cells transfected with GFP-
wtSOD1 or GFP-G93A-SOD1. Upper insets, NSC34 cells; middle
insets, proliferating C2C12 cells (C2C12 cells); lower insets, differ-
entiating C2C12 cells (C2C12-D cells). GFP kex = 488 nm,
kem = 509 nm. Images taken at 63·. Scale bar = 10 lm. (b) Flow
cytoﬂuorimetric analysis of NSC34, C2C12 and C2C12-D cells
expressing soluble EGFP protein, evaluating the number of EGFP-
positive cells in a total of 10 000 cells. (c) Quantiﬁcation of SOD1
aggregates in NSC34 and C2C12 cells, in proliferating or differenti-
ating status. t-Test analysis on wtSOD1 versus G93A-SOD1 trans-
fected cells. *p < 0.05 versus wtSOD1 transfected NSC34 cells. (d)
Western blot assay performed on cells lysates of NSC34 or C2C12
cells. NT, untransfected cells; mock, pcDNA3 transfected cells;
wtSOD1, human wtSOD1 transfected cells; G93A-SOD1, human
G93A-SOD1 transfected cells. Endogenous mouse SOD1 (mSOD1)
immunoreactivity was detected in all samples, whereas human SOD1
(hSOD1) was detected only in transfected samples. (e) Optical den-
sity analysis on human SOD1 accumulation. The histogram is ob-
tained from dots optical densities of experiments performed in
triplicate. t-Test analysis on wtSOD1 versus G93A-SOD1 transfected
cells: *p < 0.05 versus wtSOD1 transfected C2C12 cells. ***p < 0.001
versus wtSOD1 transfected C2C12-D (differentiating) cells. (f) Flow
cytoﬂuorimetric analysis of total levels of GFP-tagged wt and mutant
SOD1 expressed in NSC34, C2C12 and C2C12-D cells, normalized
for the total number of GFP-positive cells to exclude variation as a
result of different transfection efﬁciencies. t-Test analysis on wtSOD1
versus G93A-SOD1 transfected cells: ***p < 0.001 versus wtSOD1
C2C12 and C2C12-D transfected cells. (g) Filter retardation assay
performed on cell lysates of NSC34 or C2C12 cells transfected with
wt- or G93A-SOD1, in basal condition or after treatment with 10 lMo f
MG132 for 15 h. The histogram is obtained from dots optical densities
of experiments performed in triplicate (NSC34 cells: **p < 0.01
wtSOD1 versus G93A-SOD1,
###p < 0.001 wtSOD1 + MG132 versus
G93A-SOD1 + MG132,
dddp < 0.001 G93A-SOD1 versus G93A-
SOD1 + MG132; C2C12 cells:
##p < 0.01 wtSOD1 + MG132 versus
G93A-SOD1 + MG132,
ddp < 0.01 G93A-SOD1 versus G93A-
SOD1 + MG132; C2C12-D:
###p < 0.001 wtSOD1 + MG132 versus
G93A-SOD1 + MG132,
dddp < 0.001 G93A-SOD1 versus G93A-
SOD1 + MG132). (h) Flow cytoﬂuorimetric analysis of MitoSOX-po-
sitive cells. NSC34, C2C12 and C2C12-D cells were transfected with
GFP tagged SOD1, wt or G93A, and after labelled with MitoSOX
reagents. The cytoﬂuorimeter counts the number of red positive cells
that were also GFP positive. GFP kex = 488 nm, kem = 509 nm; Mit-
oSOX Red kex = 584 nm, kem = 607 nm. t-Test analysis on wtSOD1
versus G93A-SOD1 transfected cells:
***p < 0.0001 versus wtSOD1
NSC34 transfected cells.
  2011 The Authors
Journal of Neurochemistry   2011 International Society for Neurochemistry, J. Neurochem. (2011) 118, 266–280
Mutant SOD1 removal in motoneurons and muscle cells | 271(a)
(b)
(c)
(e)
(d)
Journal of Neurochemistry   2011 International Society for Neurochemistry, J. Neurochem. (2011) 118, 266–280
  2011 The Authors
272 | E. Onesto et al.results in a selective alteration of the mitochondria, a well
known target of mutant SOD1 neurotoxicity in ALS
(Pasinelli and Brown 2006; Pedrini et al. 2010). To test
this hypothesis, we analysed MitoSOX  Red oxidation
induced by superoxide. In fact, once in the mitochondria,
MitoSOX exhibits red ﬂuorescence selectively after its
oxidation by superoxide, but not by other oxygen and/or
nitrogen reactive species. Importantly, the MitoSOX oxida-
tion is prevented by the SOD1 activity. The results are
shown in Fig. 1h. It appears that, in NSC34 cells, a
signiﬁcant increase in MitoSOX oxidation is detectable in
presence of mutant SOD1 compared with wtSOD1. No
difference is observed in the MitoSOX oxidation in C2C12
cells expressing either wt or mutant SOD1, both in their
proliferating or differentiating status. This clearly indicated
that NSC34 cells expressing mutant SOD1 are more
sensitive to a superoxide-induced oxidative stress than
wtSOD1 cells (see also Sau et al. 2007; Crippa et al.
2010b). The removal of mutant SOD1 from C2C12 cells
seems to protect against this toxic insult.
Comparison of mutant SOD1 effects on proteasomal
activity in motoneurons and muscle cells
On this bases, we decided to further analyse the role of
proteasome in the removal of mutant SOD1. Initially, we
focus our attention on the levels of sodium dodecyl sulfate-
soluble SOD1 (monomeric species detectable at the correct
M.W. in western blot analysis. Fig. 2a). We conﬁrmed that,
in motoneuronal NSC34 cells (Fig. 2a, upper inset) the total
amount of monomeric mutant SOD1 was slightly lower than
that detected for wtSOD1. Conversely, in proliferating
muscle C2C12 cells (Fig. 2a, middle inset), in absence of
MG132 (with a fully functional proteasome system), the
levels of mutant SOD1 were found to be greatly reduced
when compared with those measured for wtSOD1. This
difference was abolished when the clearance of wt or mutant
SOD1 was blocked by proteasome inhibition. In fact, we
found that proteasome inhibition with MG132 in NSC34
and proliferating C2C12 resulted in an increased level of
wt or mutant SOD1s. This effect was particularly evident
in proliferating C2C12 cells expressing mutant SOD1,
suggesting that the very low mutant SOD1 levels found in
basal condition, in these cells, are possibly caused by an
higher protein clearance mediated by the proteasome
(Fig. 2a).
Surprisingly, in differentiating muscle C2C12, proteasome
inhibition resulted in a dramatic increase of the wtSOD1,
whereas mutant SOD1 levels were not increased when
proteasome was blocked (Fig. 2a, C2C12-D lower inset); this
is apparently in contrast with the data showing an accumu-
lation of insoluble mutant SOD1 after proteasome inhibition
in the same type of cells (compare with Fig. 1g). It is
conceivable that, in these conditions, an alternative pathway
of degradation is highly active to remove the soluble
monomeric mutant SOD1 fraction during proteasome block-
age (see below).
As SOD1 clearance seems to involve the proteasome
system, we then determined whether expression of mutant
SOD1 results in alteration of the proteasome functions in
immortalized motoneurons and in muscle cells. To this
purpose, we utilized a proteasome activity reporter, the
yellow ﬂuorescent protein containing a constitutive degron
signal (CL-1) (YFPu) (Bence et al. 2001; Rusmini et al.
2007, 2010). Alterations of the proteasome activity correlate
with an accumulation of the YFPu in cells (Sau et al. 2007;
Crippa et al. 2010b). The data obtained are shown in Fig. 2b.
In this quantitative analysis, the YFPu levels (measured in
western blot) were normalized by the corresponding intra-
cellular levels of monomeric SOD1 (either wt or mutated) to
reduce variations due to SOD1 clearance in NSC34, C2C12
and C2C12-D. In agreement with our previous reports (Sau
et al. 2007; Crippa et al. 2010a; b), we found that YFPu
Fig. 2 Involvement of the proteasome in mutant SOD1 clearance in
motoneuronal NSC34 and muscle C2C12 cells. (a) Western blot assay
performed on lysates of NSC34 or C2C12 cells (proliferating or dif-
ferentiating, D), in basal condition or after treatment with 10 lMo f
MG132 for 15 h, to inhibit proteasome activity. Cells were transfected
with wt- or G93A-SOD1. NT, untransfected cells; mock, pcDNA3
transfected cells; wtSOD1, human wtSOD1 transfected cells; G93A-
SOD1, human G93A-SOD1 transfected cells. (b) Optical density
analysis of western blot assay on NSC34 cells, proliferating or differ-
entiating C2C12 cells (C2C12 and C2C12-D respectively) co-trans-
fected with hSOD1s, wt or G93A, and YFPu plasmids (a proteasome
activity reporter protein). The histogram is obtained from dots optical
densities of experiments performed in triplicate, and normalized YFPu
protein level with the corresponding monomeric hSOD1 protein.
**p < 0.01 versus wtSOD1 transfected NSC34 cells. (c) Flow cytoﬂu-
orimetric analysis on NSC34, C2C12 and C2C12-D cells co-trans-
fected with mutant G93A-SOD1s, GFPu and DsRed-Monomer
plasmids. GFPu ﬂuorescence intensity was normalized with the
number of transfected cells, evaluated as Red-positive cells. GFP
kex = 488 nm, kem = 509 nm; DsRed-Monomer kex = 557 nm,
kem = 592 nm. ***p < 0,001 versus G93A-SOD1 NSC34 expressing
cells. (d) Fluorescent microscopy analysis on cells co-transfected with
CFP-wtSOD1 or CFP-G93A-SOD1, and YFPu plasmids; cells were
analysed in basal condition or after treatment with 10 lM of MG132 for
15 h, to inhibit proteasome activity. Upper insets = NSC34 cells;
middle insets = proliferating C2C12 cells; lower insets = differentiating
C2C12 (C2C12-D) cells. CFP kex = 439 nm, kem = 476 nm; YFP
kex = 514 nm, kem = 527 nm. Images taken at 10·. Scale
bar = 10 lm. (e) Analysis of proteasome activity in motoneuronal
NSC34 and in muscle C2C12 cells, using speciﬁc AMC-conjugated
peptides. Upper inset = chimotryptic activity; middle inset = post-
acidic activity; lower inset = tryptic activity. Chimotryptic activity:
*p < 0.05 NSC34 cells versus proliferating C2C12 cells; **p < 0.01
NSC34 cells versus differentiating C2C12 cells.
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mutant SOD1. By contrast, mutant SOD1 expression in
muscle C2C12 cells (either proliferating or differentiating)
did not result in signiﬁcant YFPu accumulation. This
indicates that misfolded mutant SOD1 turnover alters
proteasome functions only in immortalized motoneurons,
but not in muscle C2C12 cells. To better evaluate the
variation of proteasome functions in presence of mutant
SOD1 in the three cell types considered, we also set up a
cytoﬂuorimetric analysis of proteasome activity. In this case,
we used a different proteasome reporter with similar
properties, the GFPu, and measured the ﬂuorescence levels
in cells expressing mutant SOD1, but normalized for the
number of transfected cells; this allowed to avoid mis-
interpretation caused by different transfection efﬁciency in
the three cell types considered. The data showed in Fig. 2c,
conﬁrmed that the impact of mutant SOD1 on proteasome
activity is very high in motoneuronal NSC34 cells, but low in
muscle C2C12 cells. Overlapping results were obtained
using ﬂuorescence microscopy analysis (Fig. 2d). In fact,
although high levels of YFPu were detectable in immortal-
ized motoneurons expressing mutant SOD1, very few
differentiating muscle cells resulted positive for YFPu. It
might be possible that proteasome activity in muscle cells is
higher than in motoneuronal cells, and this will help to
quickly remove the misfolded mutant SOD1. Alternatively,
other degradative systems might be activated in muscle cells
in response to the presence of misfolded proteins. We thus
tested the basal functions of the three different proteasome
activities (chimotryptic, post-acidic and tryptic activities) in
immortalized motoneurons in comparison to muscle C2C12
cells in the proliferating or differentiating status. The results
illustrated in Fig. 2e, showed that the post-acidic and tryptic
proteasome activities were comparable in all the three types
of cultured cells considered. Interestingly, the chimotryptic
activity was signiﬁcantly higher in proliferating muscle
C2C12 cells than in motoneuronal NSC34 cells; muscle
C2C12 cells differentiation (C2C12-D) resulted in a further
increase of the chimotryptic proteasome activity. As previ-
ously reported, only the chimotryptic activity is inhibited by
the MG132, whereas the post-acidic and tryptic activities
remained unchanged in presence of this proteasome inhibitor
(Alexandrova et al. 2008).
Comparison of the effects of mutant SOD1 on the
autophagic system in motoneuron and muscle cells
The proteasome system is one of the major intracellular
degradative pathway and acts in synergy with the autophagic
system. We thus evaluated the involvement of macroauto-
phagy by analysing the expression levels of LC3, a well
known marker of this degradative pathway. LC3 mRNA
expression levels were tested in motoneuronal NSC34, and in
muscle C2C12 cells (either in the proliferating or differen-
tiating status). The results are shown in Fig. 3a, and clearly
indicate that motoneuronal NSC34 cells expressed about 3
times more LC3-mRNA than muscle C2C12 cells grown in
basal condition. Muscle C2C12 cells differentiation (C2C12-
D) resulted in a two-fold increase of the LC3-mRNA
expression levels respect to the undifferentiated (proliferat-
ing) cells. Therefore, while motoneuronal NSC34 cells
possess a lower proteasome activity than muscle C2C12
cells, motoneuronal NSC34 cells are characterized by a much
higher potential induction of the autophagic process, indi-
cated by the increased levels of LC3-mRNA. However,
although LC3 over-induction may act as permissive factor in
autophagy, LC3 protein processing to its lipidated form LC3-
II is absolutely required to achieve autophagy activation. In
fact, to permit the complete ﬂow of the autophagosomes
from their formation to the fusion with the lysosomes, the
autophagosomes must be decorated by the lipidated LC3-II
anchored to the membrane via the phosphatidylethanolamine
(PE) tail (Garcia-Arencibia et al. 2010). Therefore, constit-
utive activation of autophagy in the three cell types was
studied by analysing the formation of the lipidated LC3-II
form in western blot analysis, and then by determining the
LC3-II/LC3-I ratio which is indicative of the levels of
autophagy in the cells (Rubinsztein et al. 2009; Mizushima
et al. 2010). The data are shown in Fig. 3b. Differentiating
muscle C2C12 cells (C2C12-D) were characterized by a very
high activation of the autophagic pathway, because the ratio
between LC3-II and LC3-I was largely in favour of the
autophagosome-anchored lipidated LC3-II form. This ratio
appeared to be much higher than that observed in prolifer-
ating muscle C2C12 cells. The constitutive activation of
autophagy in motoneuronal NSC34 cells was negligible, if
compared with the one in the muscle cell types. We then
validated these observations by analysing the intracellular
distribution of exogenous LC3 (mRFP-LC3) in ﬂuorescence
microscopy. In basal conditions, LC3 is normally diffused
into the cytoplasm, whereas during autophagy activation it
acquires a punctate distribution caused by its lipidation and
association to the autophagosomes. Figure 3c shows the
presence of largely diffused LC3 distribution in motoneuro-
nal NSC34 cells, with the presence of some autophagosomes,
indicative of basal levels of autophagic activation. Instead,
in muscle C2C12 cells, LC3 showed a more punctate
distribution, conﬁrming that in muscle cells the basal
autophagic activity is higher than in immortalized moto-
neurons.
After a characterization of autophagy in basal conditions
in the three cell types, we analysed the effects of wt or
mutant SOD1 on this degradative pathway. The results are
shown in Fig. 3d. It clearly appears that the expression of the
mutant SOD1 in motoneuronal NSC34 cells correlated with a
LC3 distribution similar to that found for wtSOD1, mainly in
a diffused form, with a slight increase of the LC3 in the
punctate distribution; this suggests the existence of a limited
autophagy activation in the presence of misfolded SOD1. In
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tiating status, constitutive autophagic activation was con-
ﬁrmed to be already present in wtSOD1 expressing cells (in
agreement with the data of Fig. 3c). However, mutant SOD1
over-expression correlated with a dramatic increase of the
punctate LC3 status indicating a potent activation of the
autophagic process in the presence of the misfolded mutant
SOD1. Moreover, in agreement with our western blot
analysis, the total levels of mutant SOD1 in muscle C2C12
cells were found greatly reduced in comparison to those
found in motoneuronal NSC34 cells. These data were then
validated with western blot analyses reported in Fig. 3e,
where we observed an increase of LC3-II in cells expressing
hSOD1s.
(a) (c)
(d)
(b)
(e)
Fig. 3 Autophagic pathway in motoneuronal NSC34 and muscle
C2C12 cells. (a) Real-time PCR analysis of LC3- mRNA levels in
basal condition in NSC34 cells and in C2C12 cells, proliferating or
differentiating (D). ***p < 0.001 proliferating C2C12 cells versus
NSC34 cells; **p < 0.01 differentiating C2C12 (C2C12-D) cells ver-
sus NSC34 cells;
##p < 0.01 differentiating (D) C2C12 cells versus
proliferating C2C12 cells. (b) Western blot assay of LC3 proteins:
lipidated (LC3-II) and unlipidated (LC3-I) LC3 in NSC34 and C2C12,
proliferating and differentiating (D) cells. The histogram is obtained
from optical densities of experiments performed in triplicate. To
evaluate autophagy activation, we analysed the ratio of LC3-II and
LC3-I. *p < 0.05 proliferating C2C12 cells and differentiating C2C12
(C2C12-D) cells versus NSC34 cells;
#p < 0.05 differentiating (D)
C2C12 cells versus proliferating C2C12 cells. (c) High resolution
ﬂuorescent microscopy analysis of cells transfected with mRFP-LC3.
mRFP kex = 584 nm, kem = 607 nm. Images taken at 63·. (d) High
resolution ﬂuorescent microscopy analysis of NSC34 and C2C12
cells co-transfected with GFP-wtSOD1 or GFP-G93A-SOD1 and
mRFP-LC3. Nuclei are stained with DAPI (blue). Upper insets =
NSC34 cells; middle insets = proliferating C2C12 cells; lower
insets = differentiating (D) C2C12 cells. GFP kex = 488 nm, kem =
509 nm; mRFP kex = 584 nm, kem = 607 nm; DAPI kex = 358 nm,
kem = 461 nm. Scale bar = 10 lm. (e) Western blot assay of LC3
protein in NSC34 and C2C12, proliferating and differentiating (D),
cells. LC3-I is the unlipidated form, LC3-II is the lipidated form of
LC3. NT, untransfected; wtSOD1, human wtSOD1 transfected cells;
G93A-SOD1, human G93A-SOD1 transfected cells.
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in muscle C2C12 cells, but limited in motoneuronal NSC34
cells, we decided to further investigate the activation of the
autophagic system using an alternative autophagic marker,
the p62. This protein is responsible for the recognition of
ubiquitinated misfolded substrates, and for their insertion
into the nascent autophagosome. Moreover, p62, as well as
LC3, is transcriptionally up-regulated during autophagy
(Nakano et al. 2004; Nakaso et al. 2004; He and Klionsky
2009). In addition, it is known that both p62 mRNA and
protein levels increased after cells damages, inhibition of
proteasome activity, presence of misfolded proteins (Bjorkoy
et al. 2006). Thus, p62 is considered a marker for the
potential of a given cell to respond to these aberrant stimuli.
Interestingly, when the autophagic ﬂux is blocked, the p62
protein levels increased as a result of the blockage of its
degradation (Klionsky et al. 2008). On these bases, we
initially compared the expression levels of p62-mRNA in the
three cell types considered, to evaluate their potential
response to aberrant stimuli. The results obtained (Fig. 4a)
showed that, in basal conditions, proliferating muscle C2C12
cells were characterized by p62-mRNA levels signiﬁcantly
lower than motoneuronal NSC34 cells. However, after being
induced to differentiate, C2C12 cells were found to express
(a)
(b)
Fig. 4 p62 expression and localization. (a)
Real-timePCRanalysisofmRNA-p62levels
in basal condition in NSC34 cells and in
C2C12 cells, proliferating or differentiating
(D). *p < 0.05 proliferating C2C12 cells ver-
sus NSC34 cells;
#p < 0.01 differentiating
(D)C2C12cellsversusC2C12cells.(b)High
resolution ﬂuorescent microscopy analysis
of NSC34 and C2C12 cells co-transfected
withGFP-wtSOD1orGFP-G93A-SOD1and
mCherry-p62. Nuclei are stained with DAPI
(blue). Upper insets = NSC34 cells; middle
insets = proliferating C2C12 cells; lower
insets = differentiating (D) C2C12 cells.
GFPkex = 488 nm, kem = 509 nm; mCherry
kex = 587 nm, kem = 610 nm; DAPI kex =
358 nm, kem = 461 nm. Images taken at
63·. Scale bar = 10 lm.
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NSC34 cells. The expression of wt or mutant SOD1 either in
motoneuronal NSC34 cells or in C2C12 cells (proliferating
or differentiating) did not signiﬁcantly modify the expression
levels either of the endogenous p62 or LC3 (data not shown).
We thus analysed the possible accumulation and the intra-
cellular distribution of exogenous p62 (mCherry-p62) in
immortalized motoneurons or muscle cells expressing wt or
mutant SOD1. The results (Fig. 4b) showed that mutant
SOD1 expression in motoneuronal NSC34 cells correlated
with a dramatic accumulation of mCherry-p62, while these
levels were much lower in wtSOD1 expressing motoneuronal
NSC34 cells. On the contrary, the mCherry-p62 levels
remained very low in muscle C2C12 cells expressing either
wt or mutant SOD1, both in proliferating and in differenti-
ating status. These data strongly agree with those obtained
using LC3 and suggest that mutant SOD1 expression results
in autophagic ﬂux blockage only in immortalized motoneu-
ronal NSC34 cells (Klionsky et al. 2008).
Discussion
In the present study, we analysed whether fALS-related
mutant SOD1 has different biochemical behaviour in moto-
neuronal and muscle cells, as well as the relative contribution
of the two major intracellular degradative pathways involved
in mutant SOD1 clearance. We found that muscle cells more
efﬁciently remove misfolded mutant SOD1 than motoneuro-
nal cells. In fact, mutant SOD1 aggregates can be easily
observed in motoneuronal cells, both in ﬂuorescence
microscopy and in ﬁlter retardation assay, whereas only
negligible amounts of insoluble mutant SOD1 are detectable
either in proliferating or differentiating muscle cells. These
data are paralleled by observations showing that the relative
degradation rate of mutant SOD1, compared with wtSOD1,
is lower in motoneuronal cells than in muscle cells (both in
proliferating and differentiating status); instead, in muscle
cells, mutant SOD1 clearance is very high. Interestingly,
proteasome inhibition resulted in the accumulation of
misfolded mutant SOD1 in all cell types, suggesting that
proteasome plays an important role in the removal of the
mutant protein both in motoneurons and in muscle cells.
However, mutant SOD1 expression leads to an impairment of
the proteasome activity only in motoneuronal cells, and not
in muscle cells. This is demonstrated by the selective
accumulation of the proteasome reporter, YFPu, in moto-
neuronal NSC34 cells, but not in muscle C2C12 cells (both
in proliferating and differentiating status). Interestingly, we
found that muscle C2C12 cells are characterized by a much
higher chimotryptic proteasome activity than motoneuronal
NSC34 cells, whereas the other two proteolytic activities of
the proteasome were comparable. Therefore, the increased
mutant misfolded SOD1 turnover in muscle cells might be, at
least in part, due to the much higher chimotryptic proteasome
activity, typical of these cells. Notably, the chimotryptic
activity greatly increased after muscle cells differentiation,
when the levels of mutant SOD1 appeared to be greatly
reduced, in comparison to proliferating (undifferentiated)
muscle cells. Moreover, MG132 inhibitory activity is
directed only against the chimotryptic activity of the
proteasome (Alexandrova et al. 2008), with no effect of the
two other proteolytic activity associated to this pathway, and
mutant SOD1 accumulates after MG132 treatment, support-
ing the notion that the chimotryptic proteasome activity is the
one responsible for the clearance of the mutant SOD1
through this pathway.
Our previous data (Crippa et al. 2010b) demonstrated that
mutant SOD1 can be removed, not only by the proteasome,
but also by alternative pathways of degradation, such as
autophagy. Surprisingly, here we found that motoneuronal
NSC34 cells are characterized by a very high mRNA
expression of the autophagic mediator LC3. In fact, LC3-
mRNA levels were found to be three times higher in
motoneuronal NSC34 cells than in proliferating muscle
C2C12 cells. LC3-mRNA slightly increased with muscle cell
differentiation, because it was twofold higher in motoneuro-
nal NSC34 cells than in differentiating muscle C2C12 cells.
Despite this, LC3 activation (conversion to the lipidated
LC3-II forms and to a punctate distribution) was much higher
in muscle C2C12 cells (both in proliferating and differen-
tiating conditions) than in motoneuronal NSC34 cells. This
indicates that autophagic system is activated at high levels in
muscle cells, and is poorly activated in motoneuronal NSC34
cells. Therefore, the higher LC3-mRNA expression, com-
bined with the low activation of LC3 observed in motoneu-
ronal NSC34 cells, apparently indicates that these cells have
the potential to activate the autophagic system, but the
efﬁciency of the activation is much lower than in muscle
C2C12 cells. The high LC3-mRNA expression in motoneu-
ronal NSC34 cells might be interpreted as the response of the
cells to satisfy a reduced potential of these cells to activate
autophagy (Rubinsztein et al. 2009; Arndt et al. 2010;
Garcia-Arencibia et al. 2010; Mizushima et al. 2010).
Notably, mutant SOD1 expression correlated with a very
high activation of LC3, in all cell types, but particularly in
muscle C2C12 and C2C12-D cells in which almost all the
LC3 was found in the lipidated form, the LC3-II, tightly
associated to the newly formed autophagosomes.
The increased LC3 expression in motoneuronal NSC34
cells might be a result of a proteasome engulfment, which
requires the activation of the alternative autophagic pathway,
triggered by the accumulating misfolded proteins. By
contrast, in muscle C2C12 cells, which are characterized
by higher chimotryptic proteasome activity, we found that,
the proteasome activity was not impaired by the mutant
SOD1 (no accumulation of YFPu), thus the LC3 levels
remained lower. It remains to be determined whether the
autophagic ﬂux is functional in the cell models considered.
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of mutant SOD1 from muscle cells has been then further
conﬁrmed by the analysis of p62 distribution in motoneuro-
nal NSC34 and muscle C2C12 cells. In fact, in immortalized
motoneuronal NSC34 cells, mutant SOD1 expression
induced a dramatic accumulation of exogenous Cherry-
labelled p62, whereas no effects were observed in muscle
C2C12 cells (both in proliferating and in differentiating
status) expressing mutant SOD1. This observation indicates
that mutant SOD1 expression correlates with an autophagic
ﬂux blockage in immortalized motoneuronal NSC34 cells.
Therefore, muscle cells are apparently more protected than
motoneuronal cells against accumulation of misfolded
mutant SOD1 in fALS. However, Dobrowolny et al.
(2008b) have recently undoubtely demonstrated in mice
models of ALS that muscle is a primary target of mutant
SOD1 toxicity (Dobrowolny et al. 2008b). In fact, the
muscle-restricted expression of the mutant SOD1 (MLC/
SOD1G93A) was sufﬁcient to induce severe muscle atrophy,
with a signiﬁcant reduction in muscle strength, sarcomere
disorganization, as well as mitochondrial alterations and
disorganization of the sarcotubular system (Dobrowolny
et al. 2008b). More recently, by producing a second
transgenic MLC/SOD1G93A ALS model, Wong and Martin
(2010) conﬁrmed the observation of Dobrowolny and
colleagues just described. In addition, they clearly demon-
strated that the MLC/SOD1G93A in transgenic mice also
correlated with the loss of spinal cord motoneurons that are
devoid of mutant SOD1 (Wong and Martin 2010). Therefore,
in ALS, motoneuron loss might also derive from the
dysfunction occurring in the muscular cells, which are also
target of mutant SOD1 toxicity. These data might appear in
contrast with our observations showing that muscle cells
respond to the presence of insoluble mutant SOD1 much
better than motoneurons. A second possible explanation
arises from very recent experimental data showing that the
activity of the proteasome system in the skeletal muscle
differs in individual muscle groups and more importantly
decreases with aging (Strucksberg et al. 2010). Moreover, a
50% reduction in speciﬁc catalytic activity of the 20S
proteasome was reported in aged rats, and a signiﬁcant
reduction in the proteasomal degradation of oxidized
calmodulin was observed in aged muscle (Ferrington et al.
2005; Husom et al. 2005). The reduced proteasome activity
seems to be due to alterations in the composition of the 20S
proteasome complex with a 50% reduction of the activating
complexes, PA28 and PA700 (Husom et al. 2005), suggest-
ing that signiﬁcant age-related changes in proteasome
structure, function, and oxidation state that could inhibit
removal of oxidized proteins (Ferrington et al. 2005; Husom
et al. 2005). Unfortunately, these aspects cannot be evaluated
in cultured muscle C2C12 cells. Finally, an alternative
explanation includes the possible differences in mutant
SOD1 aggregation in mitochondria of motoneurons or
muscle cells. In fact, it has been recently shown that removal
of aggregates in the cytosol of neuronal cells is not sufﬁcient
to rescue cells from damage induced by mutant SOD1 (Ferri
et al. 2010), whereas the removal of mutant SOD1 mito-
chondrial aggregates has positive effects on cell survival
(Ferri et al. 2010). Future studies should be devoted to
analyse possible modiﬁcation in mitochondria of motoneuron
versus muscle cells. It could also be possible that insoluble/
aggregated SOD1 is not the primary cause of toxicity. It has
been proposed that other mechanisms (formation of aberrant
free radical species, mitochondrial dysfunction, nuclear
deprotection, etc.) (Bendotti and Carri 2004; Cozzolino
et al. 2008, 2009) may play a relevant role in inducing cell
dysfunctions both in motoneurons and muscle cells, inde-
pendently from the presence of aggregates. In the transgenic
ALS mice expressing mutant SOD1 in muscle cells, it has
been demonstrated the activation of signals correlated with
oxidative stress (Dobrowolny et al. 2008b): for example,
activation of FoxO and NFkB, that are both capable to
induce the expression of several atrophy-related genes. In the
same animals, there was an accumulation of reactive oxygen
species that serves as signalling to initiate autophagy. In fact,
the muscle of these mice revealed the T-tubule as the
potential donor of membrane that forms sequestering auto-
phagocytic vesicles (Dobrowolny et al. 2008b).
All together these data indicate that muscle cells are more
resistant to the accumulation of misfolded species of the
mutant SOD1, but this might not be related to the cell
toxicity exerted by this mutant protein.
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